AU6128694A - Immunoreactive reagents employing heterodimers - Google Patents

Immunoreactive reagents employing heterodimers

Info

Publication number
AU6128694A
AU6128694A AU61286/94A AU6128694A AU6128694A AU 6128694 A AU6128694 A AU 6128694A AU 61286/94 A AU61286/94 A AU 61286/94A AU 6128694 A AU6128694 A AU 6128694A AU 6128694 A AU6128694 A AU 6128694A
Authority
AU
Australia
Prior art keywords
group
reagent
mrp14
residue
mrp8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61286/94A
Other languages
English (en)
Inventor
Christopher Douglas Valiant Black
Clyde William Shearman
Robert Allen Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU6128694A publication Critical patent/AU6128694A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU61286/94A 1993-01-28 1994-01-26 Immunoreactive reagents employing heterodimers Abandoned AU6128694A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1054493A 1993-01-28 1993-01-28
US010544 1993-01-28
PCT/US1994/000965 WO1994016741A1 (en) 1993-01-28 1994-01-26 Immunoreactive reagents employing heterodimers

Publications (1)

Publication Number Publication Date
AU6128694A true AU6128694A (en) 1994-08-15

Family

ID=21746245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61286/94A Abandoned AU6128694A (en) 1993-01-28 1994-01-26 Immunoreactive reagents employing heterodimers

Country Status (5)

Country Link
EP (1) EP0681484A1 (ja)
JP (1) JPH08509955A (ja)
AU (1) AU6128694A (ja)
CA (1) CA2154896A1 (ja)
WO (1) WO1994016741A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723242T2 (de) * 1996-03-13 2004-06-03 Bristol-Myers Squibb Pharma Co. Ternäre radiopharmazeutische komplexe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand

Also Published As

Publication number Publication date
JPH08509955A (ja) 1996-10-22
CA2154896A1 (en) 1994-08-04
WO1994016741A1 (en) 1994-08-04
EP0681484A1 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
EP0173629B1 (en) Antibody-metal ion complexes
US4741900A (en) Antibody-metal ion complexes
JP3095415B2 (ja) 免疫複合体の調製及び使用
US5807879A (en) Biotinidase-resistant biotinylated compound and methods of use thereof
US5171563A (en) Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH0749377B2 (ja) 機能的特異性抗体
JPH01294700A (ja) 追跡標識接合体
JPH06501703A (ja) 治療用及び診断用撮像組成物及び方法において役立つ錯化剤及びターゲティング放射性免疫試薬
CA2150477A1 (en) Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide
JPH06507918A (ja) ｉｎ　ｖｉｖｏ　結合対プレターゲティング
JP2792871B2 (ja) 金属イオンの除去方法およびそれに用いる溶液
EP0675737A1 (en) Immunoreactive reagents employing dihydrofolate reductase
CA2157902A1 (en) Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
CA2232601A1 (en) Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
RU2122431C1 (ru) Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент
AU7244894A (en) Immunoreactive reagents employing monoamine oxidase
Mattes Pharmacokinetics of Antibodies and their Radiolabels
AU6128694A (en) Immunoreactive reagents employing heterodimers
EP4230637A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
Pollack et al. Hydrazino-type N 2 S 2 chelators
Frey Preparation, characterization and biological evaluation of cellobiose and dextran carriers of prosthetically labeled iodine-125 for use in radioimmunotherapy of tumors of glial origin